Anifrolumab SC injection (300mg) + Anifrolumab IV infusion (300mg) + Anifrolumab SC infusion (600mg) + Anifrolumab placebo SC injection (300mg) + Anifrolumab placebo IV infusion (300mg) + Anifrolumab placebo SC infusion (600mg)

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Safety

Conditions

Safety, Pharmacokinetics, Healthy Subjects

Trial Timeline

Nov 16, 2015 → May 25, 2016

NCT ID

NCT02601625

About Anifrolumab SC injection (300mg) + Anifrolumab IV infusion (300mg) + Anifrolumab SC infusion (600mg) + Anifrolumab placebo SC injection (300mg) + Anifrolumab placebo IV infusion (300mg) + Anifrolumab placebo SC infusion (600mg)

Anifrolumab SC injection (300mg) + Anifrolumab IV infusion (300mg) + Anifrolumab SC infusion (600mg) + Anifrolumab placebo SC injection (300mg) + Anifrolumab placebo IV infusion (300mg) + Anifrolumab placebo SC infusion (600mg) is a phase 1 stage product being developed by AstraZeneca for Safety. The current trial status is completed. This product is registered under clinical trial identifier NCT02601625. Target conditions include Safety, Pharmacokinetics, Healthy Subjects.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02601625	Phase 1	Completed	Nov 16, 2015	May 25, 2016	Safety

Competing Products

20 competing products in Safety

See all competitors

Product	Company	Stage	Hype Score
LPH-5 + Placebo	Biotrial	Phase 1	25
DS-1971 + placebo	Daiichi Sankyo	Phase 1	33
ASP7962 + Placebo	Astellas Pharma	Phase 1	33
ASP2151 + Valacyclovir + Placebo	Astellas Pharma	Phase 1	33
AZD7986, oral solution, 1 to 50 mg/mL + Placebo, oral solution	AstraZeneca	Phase 1	33
AZD7594 + Placebo to match	AstraZeneca	Phase 1	33
Anastrozole ODF + Arimidex tablet + Anastrozole ODF + Arimidex tablet	AstraZeneca	Phase 1	33
AZD4721 Solution + AZD4721 Placebo + AZD4721 Suspension	AstraZeneca	Phase 1	33
AZD9977, oral suspension + Placebo, oral suspension + AZD9977, oral solution	AstraZeneca	Phase 1	33
AZD3043	AstraZeneca	Phase 1	33
AZD8848 + Placebo to match AZD8848	AstraZeneca	Phase 1	33
AZD9567 Monohydrat + Placebo oral suspension/ Placebo capsule + Prednisolone	AstraZeneca	Phase 1	33
AZD7503 + Placebo	AstraZeneca	Phase 1	33
Fluad + Saline	Novartis	Approved	85
TBM100	Novartis	Approved	85
VIB9600 + Placebos	Amgen	Phase 1	32
Denosumab	Amgen	Phase 3	76
Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil	Akeso	Phase 2	51
HTL0018318 + Placebo oral capsule	Nxera Pharma	Phase 1	32
Sildenafil + Placebo + Vardenafil (Levitra, BAY38-9456) + Placebo	Bayer	Approved	82

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved